Semaglutide linked to increased risk of severe eye condition NAION in new study

FHS
July 9, 2024
3:05 am

Research shows semaglutide users face a significantly higher risk of developing non-arteritic anterior ischemic optic neuropathy (NAION) compared to users of other medications for diabetes and obesity.

Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas | Psychedelic Invest

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based

March 18, 2024

Zimmer Biomet restructures, outlines cost-cutting strategy

By the numbers Q4 revenue: $1.94 billion 6.3% increase year over year Q4 net income: $419.2 million Compared to a net loss of $130.5 million

February 8, 2024

Preclinical biotech Metagenomi prices $94M IPO at low end of proposed range

The bouncer is letting a preclinical biotech enter the IPO club Thursday night. Yes, the timestamp is 2024. A preclinical Nasdaq offering sounds like a

February 10, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.